- Global network
- About us
-
Knowledge hub
Clinical Trial Supply & Logistics
- Clinical Trial Logistics
- Clinical Trial Supply
- Courier Services & Preconditioned Temperature Controlled Packaging
- GxP-Compliant Cold Chain Transport & Storage
- Decentralised Clinical Trials & Direct-to-Patient Logistics
- Labelling of Medicinal Products
- Laboratory Kits Preparation
- Protocol Review & Project Management
Medicines Access & Patient-Oriented Services
Regulatory & Importation Services
21.09.2026
COREX appoints Loukas Tzitzis as Chief Executive Officer
International business leadership and technology experience to support COREX’s next stage of growth
DUBLIN, Ireland, 21 September 2026: COREX, the specialist pharmaceutical supply and patient access company, has appointed Loukas Tzitzis as Chief Executive Officer to lead its continued international growth.
Loukas began his career in medical genetics research at the NHS Institute of Medical Genetics in Cardiff, before moving into international business leadership. An award-winning executive, he has held CEO and other C-level positions across a range of industries, developing international markets, improving commercial and operational performance, and building high-performing teams. Having lived in 15 countries over 30 years, he brings a broad international perspective.
Technology is reshaping clinical logistics and expectations of service. At COREX, Loukas will focus on strengthening operations, improving client service and guiding the company’s digital development.
Andrey Tarakanov, Founder of COREX, said:
“Over fifteen years, we have built deep expertise, earned the trust of our clients, and developed a team that delivers in markets most providers cannot reach. Loukas brings decades of international business leadership experience, alongside the scientific grounding, technology expertise and operational depth that COREX needs for its next chapter. His experience of leading businesses through digital change in regulated, multi-country environments will help us accelerate international growth and develop new ways to meet our clients’ evolving needs. He has my full support.”
Loukas Tzitzis, Chief Executive Officer of COREX, said:
“COREX has spent fifteen years getting the hard parts right: regulatory depth, cold-chain precision and patient access capability in markets where these things are genuinely difficult to build.
I have seen how technology can change the way businesses compete and grow. AI, digitalisation and automation offer the potential to extend the reach of specialist expertise, develop new services and deliver the responsiveness clients expect. I look forward to working with the COREX team to realise that potential and grow internationally, with quality and patient needs guiding our decisions.”
About COREX
COREX provides clinical trial logistics, comparator sourcing and managed access programmes, including Named Patient Programmes (NPP), Expanded Access Programmes (EAP) and Post-Trial Access (PTA), across more than 45 markets globally. The company is headquartered in Dublin, Ireland.
DUBLIN, Ireland, 21 September 2026: COREX, the specialist pharmaceutical supply and patient access company, has appointed Loukas Tzitzis as Chief Executive Officer to lead its continued international growth.
Loukas began his career in medical genetics research at the NHS Institute of Medical Genetics in Cardiff, before moving into international business leadership. An award-winning executive, he has held CEO and other C-level positions across a range of industries, developing international markets, improving commercial and operational performance, and building high-performing teams. Having lived in 15 countries over 30 years, he brings a broad international perspective.
Technology is reshaping clinical logistics and expectations of service. At COREX, Loukas will focus on strengthening operations, improving client service and guiding the company’s digital development.
Andrey Tarakanov, Founder of COREX, said:
“Over fifteen years, we have built deep expertise, earned the trust of our clients, and developed a team that delivers in markets most providers cannot reach. Loukas brings decades of international business leadership experience, alongside the scientific grounding, technology expertise and operational depth that COREX needs for its next chapter. His experience of leading businesses through digital change in regulated, multi-country environments will help us accelerate international growth and develop new ways to meet our clients’ evolving needs. He has my full support.”
Loukas Tzitzis, Chief Executive Officer of COREX, said:
“COREX has spent fifteen years getting the hard parts right: regulatory depth, cold-chain precision and patient access capability in markets where these things are genuinely difficult to build.
I have seen how technology can change the way businesses compete and grow. AI, digitalisation and automation offer the potential to extend the reach of specialist expertise, develop new services and deliver the responsiveness clients expect. I look forward to working with the COREX team to realise that potential and grow internationally, with quality and patient needs guiding our decisions.”
About COREX
COREX provides clinical trial logistics, comparator sourcing and managed access programmes, including Named Patient Programmes (NPP), Expanded Access Programmes (EAP) and Post-Trial Access (PTA), across more than 45 markets globally. The company is headquartered in Dublin, Ireland.